Cross-Platform Evaluation of Commercial Metabolomics Platforms to Support Precision Therapeutics Research

As part of its RAPID-DxTM (Research Alliance for Precision Therapeutics, Innovation and Diagnostics) program, researchers from Cohen Veterans Bioscience (CVB) and collaborators conducted a blinded cross-platform analysis (or "bakeoff") of commercially available assay platforms to inform selection in the conduct of neuropsychiatric biomarker research.

Share this article:

More from CVB

https://www.cohenveteransbioscience.org/wp-content/uploads/2023/02/cvb-pr-2-21-23-data-visualization-featuredimage.jpg

Untapped potential of machine learning techniques for Parkinson’s Disease research and healthcare

https://www.cohenveteransbioscience.org/wp-content/uploads/2022/12/btb-action-summit-mh-cropped.jpg

Cohen Veterans Bioscience Announces ‘Call for National TBI Action Coalition’

About Cohen Veterans Bioscience (CVB)

Cohen Veterans Bioscience is a non-profit 501(c)(3) biomedical research and technology organization dedicated to advancing brain health by fast-tracking precision diagnostics and tailored therapeutics.

For Media Inquiries

Please feel free to email us at media@cohenbio.org